BioReference Health (clinical, women's health, urology and 4Kscore assets)
→
LabCorp
Asset Acquisition · Cash plus earnout · LH · announced Oct 15, 2026
Announced
Oct 15, 2026
Economics
Cash plus earnout
$722M cash at closing per OPKO 8-K Item 1.01, subject to upward or downward adjustment based on Business revenues at closing; up to $150M additional earnout (total potential $872M). Select-asset purchase (Asset Purchase Agreement dated Oct 14, 2026), not a whole-company acquisition. Pending: subject to HSR clearance; outside date Apr 14, 2027; $28.88M Buyer termination fee on specified regulatory failure. No closedDate until a completion filing or release.
Target
BioReference Health (clinical, women's health, urology and 4Kscore assets)
Diagnostics · Diagnostic / genomic
HQ Elmwood Park, NJ
Select assets of OPKO Health subsidiary BioReference Health under agreement to Labcorp in 2026: laboratory testing businesses focused on clinical and women's health testing, urology and corrections, over 80 patient service centers and the proprietary 4Kscore prostate cancer test; follows BioReference's 2024 sale of clinical diagnostics and reproductive and women's health assets outside NY/NJ to Labcorp (c152)
- SEC EDGAR - OPKO Health 8-K Item 1.01 (Oct 15, 2026; Asset Purchase Agreement dated Oct 14, 2026) https://www.sec.gov/Archives/edgar/data/944809/000119312526422877/opk-20261014.htm
- Labcorp press release via PR Newswire (Oct 15, 2026) https://ir.labcorp.com/news-releases/news-release-details/labcorp-enters-agreement-opko-health-acquire-select-assets
- Labcorp press release via PR Newswire (Mar 28, 2024; About BioReference Health: "Headquartered in Elmwood Park, New Jersey") https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-acquisition-select-assets-bioreference-healths
Acquirer
LabCorp (LH)
Diagnostics
HQ Burlington, NC
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Labcorp acquires BioReference Health's laboratory testing businesses focused on clinical and women's health testing services, urology, corrections and certain operational assets, including over 80 additional patient service centers, plus the proprietary 4Kscore Test
Evidence ladder
Primary (regulatory / filing)
SEC EDGAR 8-K Item 1.01 (OPKO Health, Oct 15, 2026) https://www.sec.gov/Archives/edgar/data/944809/000119312526422877/opk-20261014.htm
Open sourceSecondary (press / IR)
Labcorp press release (Oct 15, 2026) https://ir.labcorp.com/news-releases/news-release-details/labcorp-enters-agreement-opko-health-acquire-select-assets
Open sourceTertiary (trade / analyst)
CLP Magazine coverage (Oct 15, 2026) https://clpmag.com/lab-management/company-news/labcorp-acquires-bioreference-health-assets-4kscore-test/
Open source
Limitations
- $722M cash at closing per OPKO 8-K Item 1.01, subject to upward or downward adjustment based on Business revenues at closing; up to $150M additional earnout (total potential $872M). Select-asset purchase (Asset Purchase Agreement dated Oct 14, 2026), not a whole-company acquisition. Pending: subject to HSR clearance; outside date Apr 14, 2027; $28.88M Buyer termination fee on specified regulatory failure. No closedDate until a completion filing or release.
Valuation peers · Diagnostics
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.
| Why included | ||||
|---|---|---|---|---|
| BioReference Health (clinical diagnostics and reproductive & women's health, outside NY/NJ) | LabCorp | Mar 28, 2024 | same evidence class · same acquirer |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Vs this deal | ||||
|---|---|---|---|---|
| Invitae Reproductive Health | Natera | Jan 22, 2024 |
Other verified deals by LabCorp
Acquirer program history not already listed as a valuation peer or adjacency row.
| Sector | ||||
|---|---|---|---|---|
| Ovia Health | LabCorp | Aug 12, 2021 | Undisclosed | Maternal Health |
| Sequenom | LabCorp | Jul 27, 2016 | Diagnostics |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — BioReference Health (clinical, women's health, urology and 4Kscore assets) (Diagnostics). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v11 · updated 2026-10-19 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.